With almost two more years having passed since the company successfully lobbied the FDA to expand its Nerivio neuromodulation armband indication as an acute migraine treatment from adults only to all patients aged 12 and older with episodic or chronic migraine, Theranica is once again asking the agency to expand the device’s approved usage.

Its latest submission would position the wearable as a preventive migraine therapy in addition to its current use as an acute, on-demand treatment—making it a “much more important and impactful therapy,”